Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.88 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.65 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.63 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.63 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 1/20 | 0.62 |
| ▸ | PPARD | Q03181 | 1/20 | 0.62 |
| ▸ | PPARA | Q07869 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746597 | 0.93 | FFAR1 (1.00) | FFAR1FFAR4LMNAL3MBTL1S1PR1 | |
| SCHEMBL8213476 | 0.92 | FFAR1 (0.81) | FFAR1FFAR4LMNAL3MBTL1SRD5A2 | |
| SCHEMBL4656572 | 0.92 | FFAR1 (0.97) | FFAR1FFAR4LMNAL3MBTL1S1PR1 | |
| SCHEMBL8767174 | 0.92 | FFAR1 (0.79) | FFAR1FFAR4LMNAL3MBTL1S1PR1 | |
| SCHEMBL1744690 | 0.92 | FFAR1 (1.00) | FFAR1FFAR4LMNAL3MBTL1S1PR1 | |
| SCHEMBL8767670 | 0.90 | FFAR1 (0.72) | FFAR1FFAR4LMNAL3MBTL1S1PR1 | |
| SCHEMBL1745370 | 0.90 | FFAR1 (1.00) | FFAR1FFAR4LMNAL3MBTL1S1PR1 | |
| SCHEMBL24723561 | 0.87 | L3MBTL1 (0.82) | FFAR1LMNAL3MBTL1S1PR1S1PR3 | |
| SCHEMBL1532487 | 0.87 | FFAR1 (0.72) | FFAR1FFAR4LMNAL3MBTL1S1PR1 | |
| SCHEMBL4532106 | 0.87 | FFAR1 (0.68) | FFAR1FFAR4LMNAL3MBTL1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498460-B2 | Isophthalic acid derivatives | BAYER HEALTHCARE AG (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1572628-B1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1740540-A1 | PHENYL ACETAMIDES | Bayer HealthCare AG (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-20060154912-A1 | Isophtalic acid derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-13 | — | — | US | disclosed |
| WO-2005103001-A1 | PHENYL ACETAMIDES | BAYER HEALTHCARE AG (DE) | 2005-11-03 | — | — | WO | disclosed |
| EP-1572628-A1 | ISOPHTALIC ACID DERIVATIVES | Bayer HealthCare AG (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052839-A1 | ISOPHTALIC ACID DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-06-24 | — | — | WO | disclosed |
| EP-0791576-A2 | Leukotriene antagonistic benzoic acid derivatives | BAYER AG (DE) | 1997-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154912-A1 | Isophtalic acid derivatives | VHL, FABP3, CPT1A | FFAR1 832/4885FFAR4 1065/4885LMNA 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.